Drug regimens for systemic vasculitis
Tags: VASCULITIS -- Treatment
Related Articles
- Current Regimens for Systemic Vasculitis Still Too Toxic. // Kidney;Jan/Feb98, Vol. 7 Issue 1, p20
Assesses the optimum treatment regimens and duration of treatment for prednisolone and cyclophosphamide as therapy for systemic vasculitis (SV). Risk factors for the development of leukopenia; Tendency toward increased toxicity in patients treated with the continuous regimen.
- Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. Jourde, No�mie; Mancini, Julien; Chiche, Laurent // New England Journal of Medicine;3/26/2009, Vol. 360 Issue 13, p1358
A letter to the editor is presented in response to the article "Azathioprine or Methotrexate Maintenance for ANCA-associated Vasculitis," by C. Pagnoux, A. Mahr, M.A. Hamidou, et al. published in the December 25, 2008 issue.
- Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. Gelber, Allan C. // New England Journal of Medicine;3/26/2009, Vol. 360 Issue 13, p1358
A letter to the editor is presented in response to the article "Azathioprine or Methotrexate Maintenance for ANCA-associated Vasculitis," by C. Pagnoux, A. Mahr, M.A. Hamidou, et al. published in the December 25, 2008 issue.
- Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. Pagnoux, Christian; Guillevin, Lo�c // New England Journal of Medicine;3/26/2009, Vol. 360 Issue 13, p1358
The authors reply to letters written in response to the article "Azathioprine or Methotrexate Maintenance for ANCA-associated Vasculitis," published in the December 25, 2008 issue.
- Rheumatoid Vasculitis: Effect of Cyclophosphamide on the Clinical Course and Levels of Circulating Immune Complexes. Abel, Thomas; Andrews, Brian S.; Cunningham, Polley H.; Brunner, Carolyn M.; Davis, John S.; Horwitz, David A. // Annals of Internal Medicine;Sep80, Vol. 93 Issue 3, p407
Presents information on a study which described the experience of treatment with cyclophosphamide in patients with severe rheumatoid vasculitis. Measurement of immune complexes in serum; Case reports presented; Effect of cyclophosphamide on immunologic indexes; Measurement of the levels of...
- Livedoid vasculitis helped by short-term fibrinolytic tx. Guttman, Cheryl // Dermatology Times;Jul95, Vol. 16 Issue 7, p4
Focuses on the effectiveness of short-term fibrinolytic therapy in controlling livedoid vasculitis, reported by Gregory L. Perez at the Society for Investigative Dermatology's 56th annual meeting. Increase in activity and quantity level of plasminogen activating inhibitor (PAI); Higher tissue...
- Combination therapy in autoimmune disease: vasculitis. Carruthers, D.; Bacon, P. // Springer Seminars in Immunopathology;Jun2001, Vol. 23 Issue 1/2, p91
Examines the results of using combination therapy in treating autoimmune diseases such as vasculitis. Aims of the therapy; Effects of the combined results of individual therapies; Factors that result in remission.
- Predetermined Goals Seek to Improve Outcome in ANCA-Associated Vasculitides. // Kidney;May/Jun98, Vol. 7 Issue 3, p114
Discusses the abstract of the research paper entitled 'Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group,' by D.R.W. Jayne and N. Rasmussen and published in a 1997 issue of the...
- Leukocytoclastic Vasculitis in a Patient with HHV-6 Infection. Drago, Francesco; Rampini, Paolo; Brusati, Carlo; Rebora, Alfredo // Acta Dermato-Venereologica;Jan2000, Vol. 80 Issue 1, p68
Examines the development of leukocytoclastic vasculitis in a patient with human herpes virus-6 (HHV-6) infection. Exhibition of papular-purpuric lessions with sparse petechiae upon examination; Effects of HHV-6 in early childhood; Use of deflazacort in treating the disease.
